Evidence and Risks by Condition

Kratom dependence and withdrawal, and the early but growing interest in ibogaine as an alternative to conventional opioid-receptor tapering.

Opioid use disorder, and ibogaine's six-decade history as the original and most-studied use case for addiction interruption.

Heroin dependence and withdrawal, the use case that first brought ibogaine to clinical attention in the 1960s.

Post-traumatic stress disorder, and the growing body of veteran-focused research behind ibogaine as a trauma treatment.

Major depressive disorder, and why ibogaine's evidence base here is among the strongest of any condition on this site.

Alcohol use disorder, and the emerging but still limited clinical data on ibogaine as an alternative to naltrexone and acamprosate.

Cocaine dependence, and ibogaine's multi-receptor profile as a candidate for a disorder with no FDA-approved medication.

Methamphetamine addiction, and the thinner, still-developing evidence for ibogaine where no approved medications exist.

Anxiety disorders, and why no direct clinical trials yet test ibogaine specifically for anxiety alone.

Traumatic brain injury, and the observational veteran studies behind ibogaine's neuroplasticity claims.

Chronic Lyme disease, and why the evidence for ibogaine here is almost entirely anecdotal.

Buprenorphine (Suboxone/Subutex) dependence, and ibogaine's role in one of the hardest opioid detoxes to complete.

Methadone dependence, and ibogaine's decades-long history addressing one of the hardest opioids to discontinue.

Obsessive-compulsive disorder and whether ibogaine shows any evidence as an intervention.

Smoking and nicotine dependence, and the limited evidence for ibogaine as a cessation aid.

Parkinson's disease, and why no published clinical research tests ibogaine for Parkinson's in humans at all yet.

Bipolar I and II disorder, and the safety concerns around ibogaine use in people with this diagnosis.

Compulsive pornography use and sex addiction, and the thin evidence base for ibogaine in behavioral (non-substance) addictions.

A single industry-funded case report describes two MS patients with notable brain scan changes after ibogaine treatment. No controlled trials exist. Here's an honest look at the evidence and its limits.

Fentanyl and illicitly manufactured fentanyl analogs present distinct screening and safety considerations compared to other opioids, due to fentanyl's high lipophilicity and tissue accumulation with regular use. This category lets centers indicate specific experience treating fentanyl-dependent patients.